Conjunctival Lymphoma in a Patient on Fingolimod for Relapsing-Remitting Multiple Sclerosis

被引：8
|
作者：
Christopher, Karen L. [1 ]
Elner, Victor M. [1 ]
Demirci, Hakan [1 ]
机构：
[1] Univ Michigan, Dept Ophthalmol & Visual Sci, WK Kellogg Eye Ctr, 1000 Wall St, Ann Arbor, MI 48109 USA
来源：
OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY | 2017年 / 33卷 / 03期
关键词：
B-CELL LYMPHOMA; RITUXIMAB;
D O I：
10.1097/IOP.0000000000000774
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
The authors describe a 39-year-old woman treated with fingolimod for relapsing-remitting multiple sclerosis for 2 years who then developed a bilateral conjunctival mucosa-associated lymphoid tissue lymphoma. Fingolimod treatment for multiple sclerosis has been associated with lymphoma in 3 previously reported cases. This is the first case of ocular adnexal lymphoma presumed to be due to fingolimod. Given that ophthalmologists regularly monitor many patients on fingolimod for fingolimod-associated macular edema and ophthalmic manifestations of multiple sclerosis, the authors hope to alert physicians of the possibility of ocular adnexal lymphoma in these patients.
引用
收藏
页码：E73 / E75
页数：3
相关论文
共 50 条
  • [31] Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
    Shima, Ayano
    Hamaguchi, Tsuyoshi
    Tada, Yasutake
    Yamada, Masahito
    INTERNAL MEDICINE, 2020, 59 (01) : 121 - 124
  • [32] Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell Depletion
    Shirani, Afsaneh
    Stuve, Olaf
    Cross, Anne H.
    NEUROLOGIC CLINICS, 2024, 42 (01) : 137 - 153
  • [33] Monoclonal antibodies in disease-modifying treatment of relapsing-remitting subtype of multiple sclerosis - current status and future perspectives
    Sarnecki, Kamil
    Stadnik, Marta
    Neurol, Robert Krysiak C. Aktualn
    Okopien, Boguslaw
    AKTUALNOSCI NEUROLOGICZNE, 2012, 12 (01): : 30 - 39
  • [34] Cost-Utility Analysis Comparing Ocrelizumab vs Rituximab in the Treatment of Relapsing-Remitting Multiple Sclerosis: The Colombian Perspective
    Navarro, Cristian E.
    Betancur, John E.
    VALUE IN HEALTH REGIONAL ISSUES, 2023, 36 : 83 - 91
  • [35] Fingolimod: an Oral Disease-Modifying Therapy for Relapsing Multiple Sclerosis
    Yeh, E. Ann
    Weinstock-Guttman, B.
    ADVANCES IN THERAPY, 2011, 28 (04) : 270 - 278
  • [36] Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study
    Zhao, Daidi
    Zhao, Cong
    Lu, Jiarui
    Han, Yu
    Sun, Tangna
    Ren, Kaixi
    Ma, Chao
    Zhang, Chao
    Li, Hongzeng
    Guo, Jun
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 70
  • [37] The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis
    Asha, Mohammad Z., I
    Al-Asaad, Yousef
    Khalil, Sundos F. H.
    IBRO NEUROSCIENCE REPORTS, 2021, 11 : 103 - 111
  • [38] INEBILIZUMAB Anti-CD19 MAb Treatment of neuromyelitis optica Treatment of relapsing-remitting multiple sclerosis Treatment of B-cell malignancies
    Haddley, K.
    DRUGS OF THE FUTURE, 2016, 41 (01) : 9 - 14
  • [39] Real-World Comparative Cost-Effectiveness Analysis of Different Classes of Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in Saudi Arabia
    AlRuthia, Yazed
    Balkhi, Bander
    Alkhalifah, Sahar Abdullah
    Aljarallah, Salman
    Almutairi, Lama
    Alanazi, Miteb
    Alajlan, Abdulmalik
    Aldhafiri, Suliman M.
    Alkhawajah, Nuha M.
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (24)
  • [40] Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
    Rezaee, Mehdi
    Morowvat, Mohammad Hossein
    Poursadeghfard, Maryam
    Radgoudarzi, Armin
    Keshavarz, Khosro
    BMC HEALTH SERVICES RESEARCH, 2022, 22 (01)
12345